Idioma:

The HIV-Brazil cohort study: design, methods and participant characteristics

Grangeiro, Alexandre ; Escuder, Maria Mercedes ; Cassenote, Alex Jones Flores ; Cassanote, Alex Jones Flores ; Souza, Rosa Alencar ; Kalichman, Artur O ; Veloso, Valdiléa G ; Veloso, Valdiléa ; Ikeda, Maria Letícia Rodrigues ; Barcellos, Nêmora Tregnago ; Brites, Carlos ; Tupinanbás, Unai ; Lucena, Noaldo O ; da Silva, Carlos Lima ; Lacerda, Heloisa Ramos ; Grinsztejn, Beatriz ; Castilho, Euclides Ayres Boulle, Andrew

PloS one, 2014-05, Vol.9 (5), p.e95673-e95673 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por

Enviar para

Título:
The HIV-Brazil cohort study: design, methods and participant characteristics
Autor: Grangeiro, Alexandre ; Escuder, Maria Mercedes ; Cassenote, Alex Jones Flores ; Cassanote, Alex Jones Flores ; Souza, Rosa Alencar ; Kalichman, Artur O ; Veloso, Valdiléa G ; Veloso, Valdiléa ; Ikeda, Maria Letícia Rodrigues ; Barcellos, Nêmora Tregnago ; Brites, Carlos ; Tupinanbás, Unai ; Lucena, Noaldo O ; da Silva, Carlos Lima ; Lacerda, Heloisa Ramos ; Grinsztejn, Beatriz ; Castilho, Euclides Ayres
Boulle, Andrew
Assuntos: Acquired immune deficiency syndrome ; Adolescent ; Adult ; Adults ; Aged ; Aged, 80 and over ; AIDS ; Analysis ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Antiretroviral Therapy, Highly Active ; Antiviral agents ; Biology and Life Sciences ; Brazil - epidemiology ; CD4 antigen ; CD4 Lymphocyte Count ; Cohort analysis ; Cohort Studies ; Comorbidity ; Efavirenz ; Epidemics ; Female ; Follow-Up Studies ; Geography ; Health aspects ; Health care ; Health services ; Highly active antiretroviral therapy ; HIV ; HIV (Viruses) ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; HIV Infections - transmission ; HIV patients ; Human immunodeficiency virus ; Humans ; Immunology ; Information systems ; Lopinavir ; Lymphocytes T ; Male ; Medicine and health sciences ; Methods ; Middle Aged ; Morbidity ; Mortality ; Patients ; Preventive medicine ; Public health ; Quality of Life ; Research and Analysis Methods ; Risk Factors ; Ritonavir ; T cells ; Treatment Outcome ; Viral Load ; Young Adult
É parte de: PloS one, 2014-05, Vol.9 (5), p.e95673-e95673
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors declare that the co-author Beatriz Grinsztejn is a PLOS ONE Editorial Board member. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: AG MME RAS AOK VV MLRI NTB CB UT NOL CALS HRL BG EAC. Performed the experiments: RAS AOK VV NTB CB BG MLRI UT NOL CALS HRL. Analyzed the data: AG MME AJFC EAC. Wrote the paper: AG MME AJFC RAS AOK VV MLRI NTB CB UT NOL CALS HRL BG EAC.
Descrição: The HIV-Brazil Cohort Study was established to analyze the effectiveness of combination antiretroviral therapy (cART) and the impact of this treatment on morbidity, quality of life (QOL) and mortality. The study design, patients' profiles and characteristics of cART initiation between 2003 and 2010 were described. Since 2003, the HIV-Brazil Cohort has been following HIV-infected adults receiving cART at 26 public health care facilities, using routine clinical care data and self-reported QOL questionnaires. When not otherwise available, data are obtained from national information systems. The main outcomes of interest are diseases related or unrelated to HIV; suppression of viral replication; adverse events; virological, clinical and immunological failures; changes in the cART; and mortality. For the 5,061 patients who started cART between 2003 and 2010, the median follow-up time was 4.1 years (IQR 2.2-5.9 years) with an 83.4% retention rate. Patient profiles were characterized by a predominance of men (male/female ratio 1.7∶1), with a mean age of 36.9 years (SD 9.9 years); 55.2% had been infected with HIV via heterosexual contact. The majority of patients (53.4%) initiated cART with a CD4+ T-cell count ≤200 cells/mm3. The medications most often used in the various treatment regimens were efavirenz (59.7%) and lopinavir/ritonavir (18.2%). The proportion of individuals achieving viral suppression within the first 12 months of cART use was 77.4% (95% CI 76.1-78.6). Nearly half (45.4%) of the patients presented HIV-related clinical manifestations after starting cART, and the AIDS mortality rate was 13.9 per 1,000 person-years. Results from cART use in the daily practice of health services remain relatively unknown in low- and middle-income countries, and studies with the characteristics of the HIV-Brazil Cohort contribute to minimizing these shortcomings, given its scope and patient profile, which is similar to that of the AIDS epidemic in the country.
Editor: United States: Public Library of Science
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The HIV-Brazil cohort study: design, methods and participant characteristics

United States: Public Library of Science

Buscando em bases de dados remotas. Favor aguardar.